KRT18 and metabolic dysfunction-associated steatotic liver disease: Meta-analysis of several studies provide clues about the role of FGF-21 as a key regulator of hepatic lipid metabolism in humans and suggest that serum FGF-21 can be used as a biomarker for NAFLD, being the most promising in combination with other markers, such as CK-18 [24].